TRAIL Polyclonal Antibody
簡(jiǎn)要描述：TRAIL Polyclonal Antibody宿主: Polyclonal, Rabbit,IgG反應(yīng)性: Human;Rat;Mouse;應(yīng)用: WB;IHC;IF;ELISA
產(chǎn)品型號(hào)： YP-Ab-00578
所屬分類：多克隆抗體
更新時(shí)間：2024-10-31
詳細(xì)說明：
TRAIL Polyclonal Antibody
抗體，也叫免疫球蛋白（Ig），是一種能特異性結(jié)合抗原的糖蛋白，而抗原是在易感染動(dòng)物體內(nèi)引發(fā)抗體產(chǎn)生的物質(zhì)。在體內(nèi)，抗體是由于外源性分子的侵襲而產(chǎn)生的。抗體以一個(gè)或者多個(gè)Y字形單體存在，每個(gè)Y字形單體由4條多肽鏈組成，包含兩條相同的重鏈和兩條相同的輕鏈。輕鏈和重鏈?zhǔn)歉鶕?jù)它們的分子量大小來命名的。Y字形結(jié)構(gòu)的頂端是可變區(qū)，為抗原結(jié)合部位。任何一個(gè)抗體的輕鏈都可以分為κ或λ型（基于小分子多肽結(jié)構(gòu)上的差異），每一個(gè)抗體的重鏈則決定了它的類或型。
產(chǎn)品詳情
TRAIL Polyclonal Antibody detects endogenous levels of TRAIL protein.
免疫原詳細(xì)信息
The antiserum was produced against synthesized peptide derived from the Internal region of human TNFSF10. AA range:31-80
相關(guān)試劑
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
背景
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. This protein binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG. The activity of this protein may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannot induce apoptosis. The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
天津俊達(dá)生物科技有限公司，是從事實(shí)驗(yàn)室耗材銷售的現(xiàn)代化生物科技企業(yè)，公司本著“誠(chéng)信為本，互利共贏"的核心價(jià)值觀，秉承“以市場(chǎng)為導(dǎo)向，提供服務(wù)"的宗旨為各大院校、科研單位、第三方實(shí)驗(yàn)室檢測(cè)機(jī)構(gòu)等提供的產(chǎn)品和服務(wù)。目前公司主要經(jīng)營(yíng)分子生物學(xué)、細(xì)胞生物學(xué)、免疫學(xué)等生物學(xué)產(chǎn)品，多種實(shí)驗(yàn)室耗材 歡迎垂詢！
備注：圖片僅供參考。僅供科研，不可用于臨床。
